Etodolac (Lodine^®): Profile of an established selective COX-2 inhibitor

Author: Jones, Richard A.¹

Source: Inflammopharmacology, Volume 9, Numbers 1-2, 2001 , pp. 63-70(8)

Publisher: VSP, an imprint of Brill

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

Etodolac was developed in a search for a novel NSAID with an improved efficacy/side effect profile and was launched in the UK in 1985 for the acute and chronic treatment of arthritic conditions. The improved safety profile of etodolac when compared with other NSAIDs posed an anomaly for which there was no explanation at that time. However, the advent of the COX-2 theory served as a possible rationale for etodolac's improved safety profile, since etodolac has consistently shown selective COX-2 inhibition and COX-1 sparing effects across a wide range of assays. Since first discovery, etodolac has demonstrated a proven track record in a large number of clinical trials in patients with OA and RA extending to 7 years duration and over 14 years of clinical use.

Keywords: NSAIDS; ETODOLAC; COX-2

Document Type: Research article

DOI: 10.1163/156856001300248335

Affiliations: 1: Shire Pharmaceuticals Limited, Andover, Hampshire, UK

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$35.00 plus tax Refund Policy